Pharma
Pfizer Inc.
19
Articles
Mentioned
Top Role
Jan 19, 2026
First Mention
Apr 11, 2026
Last Mention
18.34
Relevance Score
Intelligence Brief
Overview
Pfizer Inc. is a pharmaceutical giant with a significant focus on oncology and biosimilars, crucial in the post-COVID era as it shifts away from pandemic-driven revenue. The company is navigating the loss of exclusivity on key drugs like Xeljanz and Humira, which makes its strategic moves in biosimilars and oncology even more critical. With a strong history in vaccines, Pfizer's mRNA technology remains a cornerstone, though its COVID-19 vaccine sales have plummeted. This pivot is essential as the company seeks to maintain its competitive edge in a rapidly evolving industry.
Assets & Portfolio
Pfizer owns a robust portfolio of oncology drugs, bolstered by the $43 billion acquisition of Seagen and its ADCs. Their mRNA vaccine platform, once a pandemic powerhouse, is now being redirected towards other infectious diseases. They also hold significant biosimilar assets, competing with the likes of Amgen and Biocon. Key products include Eliquis, a top-selling anticoagulant in partnership with Bristol Myers Squibb, and legacy biologics like Enbrel.
Partnerships & Deals
Pfizer collaborates extensively with Bristol Myers Squibb on Eliquis, a blockbuster anticoagulant. They have explored AI-enabled R&D partnerships with companies like Merck, though no transformative deals have been announced. These alliances are crucial as Pfizer seeks to bolster its pipeline and offset revenue losses from patent expirations. Their oncology partnerships are particularly strategic, aiming to enhance their specialty pharmacy networks.
Pipeline & Development
Pfizer's pipeline is heavily weighted towards oncology, with an expected $6 billion in annual sales from upcoming launches. They are also advancing in the obesity drug space with danuglipron, despite some setbacks in trials. The company is investing in AI-discovered antibiotics, though this remains a nascent area. Their biosimilar pipeline is expanding, targeting the revenue gaps left by expiring patents.
Competitive Position
Pfizer is a leader in oncology and biosimilars but faces stiff competition from Merck, Eli Lilly, and Amgen. Their oncology pipeline positions them well against rivals, yet the loss of COVID-19 vaccine revenue and patent cliffs on key drugs present challenges. Competitors like AstraZeneca and Novartis are also formidable in the biosimilar space, making Pfizer's strategic investments in Seagen and other oncology assets vital.
Technology & Innovation
Pfizer is transitioning towards more advanced technologies, with a focus on mRNA and AI in drug discovery. While they have embraced AI partnerships, their integration of these technologies into the core R&D process is still developing. The company is moving away from legacy systems, but the pace of this transition is crucial to maintaining their competitive edge.
Growth Outlook
Pfizer's growth is currently consolidating, with oncology and biosimilars driving future revenue. The loss of exclusivity on major drugs like Xeljanz and Humira creates immediate revenue challenges. However, strategic acquisitions and a strong pipeline in oncology and biosimilars offer potential for steady growth. The company's ability to adapt to these shifts will determine its long-term trajectory.
Industry Trend Fit
Pfizer's capabilities align well with industry trends such as the biosimilar wave and AI-driven drug discovery. Their oncology focus positions them to benefit from value-based care models, while their biosimilar strategy addresses pricing pressures from the IRA. However, the company's ability to fully integrate AI and mRNA technologies into their pipeline will be critical as the industry continues to evolve.
Coverage Timeline
April 2026
Apr 11, 2026
Nobody at Merck will admit they’re cribbing from Pfizer’s post-COVID playbook.
Apr 11, 2026
Pfizer’s Q1 2025 disclosure showed Comirnaty revenue at just $2.2 billion for the trailing twelve months, down more than 80% from peak pandemic levels.
AI-Discovered Antibiotics Hit the Clinic: Hype, Resistance, and the Harsh Economics
Pipeline
Mentioned
Apr 11, 2026
Yes, Pfizer and Merck have explored AI-enabled R&D partnerships, but nobody has snapped up an AI antibiotic company with a transformative offer.
How Pfizer's Oncology Pipeline Drives 2025 Specialty Pharmacy Network Negotiations with PBMs
Negotiations
Primary Subject
Apr 11, 2026
Pfizer's oncology pipeline is positioned to deliver a combined $6 billion in peak annual sales from next year’s launches alone, according to recent investor guidance.
Pfizer’s 2026 Biosimilar Bets: Revenue Shifts After Enbrel and Humira Patent Cliffs
Money
Primary Subject
Apr 11, 2026
For Pfizer, which has relied on sticky legacy biologic sales for a decade, the revenue cliff is immediate and real.
Apr 11, 2026
Xeljanz, their long-standing JAK inhibitor for rheumatoid arthritis and other autoimmune conditions, has been good for just north of $2 billion a year in US sales.
Roche’s $2.1 Billion Avacta Deal: Betting Big on Drug Delivery and Oncology Engineering
Deals
Mentioned
Apr 11, 2026
Pfizer paid a staggering $43 billion for Seagen and its commercial-stage ADCs plus manufacturing.
Eli Lilly's $2.4 Billion DICE Therapeutics Bet: Pipeline Risk, Platform Ambition, and Autoimmune Expansion
Deals
Mentioned
Apr 9, 2026
You’d have to look back to the early JAK inhibitor wave, or Pfizer’s $2.1 billion play for Arena Pharmaceuticals, another bet on autoimmune innovation.
GSK Names First Chief Diversity Officer Amidst Regulatory Challenges and Product Pipeline Expansion: Strategic Implications
People
Mentioned
Apr 9, 2026
For example, only 13 percent of participants in GSK’s pivotal RSV vaccine trial (US arm) identified as nonwhite, compared to 24 percent in Pfizer’s comparable trial, per ClinicalRx.ai data.
Novartis Spins Off Sandoz: What the $10B Pure-Play Means for Biosimilar Strategies and Drug Pricing 2025-2026
Deals
Competitor
Apr 7, 2026
Sandoz is up against heavyweights like Amgen, Pfizer, Biocon, and Korean giants in biosimilars.
Apr 2, 2026
Last year, the drug raked in over $13 billion in US sales for Bristol Myers Squibb and Pfizer.
March 2026
The Week in Pharma: Lilly Bets $2.5B on Alzheimer’s, Pfizer Shifts Oncology Gears, Policy Upheaval Hits Drug Discovery
The Week
Primary Subject
Mar 14, 2026
Pfizer on Wednesday laid industry rumors to rest: the company is exiting its weaker early-stage oncology bets.
February 2026
Feb 24, 2026
With biosimilars flooding in, the PBM rebate game has dramatically altered net costs, big payers now report Humira spend down by 20% or more, based on recent RxNews.ai reporting.
Feb 21, 2026
Privately, though, deal insiders acknowledge that competitive heat, especially from Pfizer and AstraZeneca, both eyeing similar bispecific assets, forced Merck’s hand.
Late-Stage Obesity Drugs Beyond GLP-1s: Orforglipron, Survodutide, and the Oral Alternatives That Could Reshape Pricing
Pipeline
Mentioned
Feb 18, 2026
The late-stage field is crowded: Altimmune’s pemvidutide, Pfizer’s danuglipron, other oral peptide mimetics, trials are everywhere.
IRA Price Negotiation Year One: What the Numbers Reveal About CMS, Drugmakers, and the Real Deals
Policy
Mentioned
Feb 5, 2026
The rebate potential made them a tempting target, and manufacturers lacked near-term legal roadblocks to slow the process.
January 2026
Obesity Pipeline Beyond GLP‑1s: Orforglipron, Survodutide, and the Oral Disruptors
Pipeline
Mentioned
Jan 27, 2026
Pfizer’s danuglipron stumbled, but Structure and Viking’s oral agents remain in Phase 2.
IRA Price Negotiation Year One: Who Blinked, Who Balked, and What's Next for Big Ticket Drugs
Policy
Mentioned
Jan 22, 2026
Eliquis (BMS/Pfizer) was among the list of drugs up for negotiation.
Jan 19, 2026
Pfizer’s Wyeth takeover? Closed at 13x trailing EBITDA.